Tuesday, 27 October 20265:12 pm ISTIndia edition

Just in

4:24 pmTwo men charged with U.K. national security offences over incident at U.S.-run military base in England
4:23 pmGruha Lakshmi beneficiaries in Karnataka used funds to increase income
4:19 pmBombay High Court stays “Leave India Notice” against actor Imran Khan till November 2
4:15 pmDays after India-Pakistan sparring at UN, senior Indian official visits Islamabad for SCO planning meet
4:15 pmSC slams Centre, drug regulator over expired Covid-era approvals for antifungal drug
SponsoredPut your announcement in this ticker from ₹69/day
4:14 pmECI’s stand that additional declaration is not part of Form 6 comes days after SC said it will examine ‘new’ Form 6
4:13 pm‘Good change’: Farooq Abdullah on expansion of J&K council of ministers
4:11 pmAbhishek and Sooryavanshi power India to T20I series win in New Zealand
4:09 pmQ2 Results Live: Bajaj Auto Profit Rises 35%, Mazagon Dock Profit Dives Over 54%, Dividend Declared
4:07 pmKarnataka’s final electoral roll published after SIR
4:05 pmCongo’s Ebola outbreak tops 10,000 cases as authorities race to slow spread in African countries
4:04 pmPolice officer booked for stealing, selling lost mobile phone in Keralam
4:03 pm'Govt allowing this to happen': Supreme Court questions overpricing of medicines, massive gap in MRP and cost to retailers
4:03 pmTamil Nadu CM Vijay announces bonus, ex gratia for ‘C’ and ‘D’ category employees in public sector undertakings
4:24 pmTwo men charged with U.K. national security offences over incident at U.S.-run military base in England
4:23 pmGruha Lakshmi beneficiaries in Karnataka used funds to increase income
4:19 pmBombay High Court stays “Leave India Notice” against actor Imran Khan till November 2
4:15 pmDays after India-Pakistan sparring at UN, senior Indian official visits Islamabad for SCO planning meet
4:15 pmSC slams Centre, drug regulator over expired Covid-era approvals for antifungal drug
SponsoredPut your announcement in this ticker from ₹69/day
4:14 pmECI’s stand that additional declaration is not part of Form 6 comes days after SC said it will examine ‘new’ Form 6
4:13 pm‘Good change’: Farooq Abdullah on expansion of J&K council of ministers
4:11 pmAbhishek and Sooryavanshi power India to T20I series win in New Zealand
4:09 pmQ2 Results Live: Bajaj Auto Profit Rises 35%, Mazagon Dock Profit Dives Over 54%, Dividend Declared
4:07 pmKarnataka’s final electoral roll published after SIR
4:05 pmCongo’s Ebola outbreak tops 10,000 cases as authorities race to slow spread in African countries
4:04 pmPolice officer booked for stealing, selling lost mobile phone in Keralam
4:03 pm'Govt allowing this to happen': Supreme Court questions overpricing of medicines, massive gap in MRP and cost to retailers
4:03 pmTamil Nadu CM Vijay announces bonus, ex gratia for ‘C’ and ‘D’ category employees in public sector undertakings

Health

Dr Reddy's bets on generic semaglutide, biosimilars

Reported by The Economic Times 26 Oct 2026, 1:19 am IST 1 min read

Image: The Economic Times. Rights remain with the publisher.

Dr Reddy's domestic formulations business grew in the September quarter, while Revlimid sales declined in North America. A relaunch of generic semaglutide and the US launch of abatacept biosimilar are anticipated for future growth. The company aims to sell millions of pens for semaglutide with a focus on international markets.

Furthermore, an expanding biosimilars portfolio aims to strengthen its position beyond traditional generics.

Read the full report on The Economic Times

Story file

Section: Health
First reported by: The Economic Times
Reporter: snehal mergu
Published: Monday, 26 October 2026, 1:19 am IST
Coverage: One outlet so far

How this page works. The Headline Update lists this report from The Economic Times with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.